Novel approach eliminates over 97% of uveal melanoma cells while sparing healthy tissue

Novel CRISPR-Cas13d RNA Therapy Shows Promise in Uveal Melanoma

Researchers at Stanford University report the development of a CRISPR-based therapeutic strategy that may open a new treatment avenue for uveal melanoma, a rare yet highly lethal ocular malignancy that has experienced minimal improvement in survival outcomes for more than five decades. By leveraging the RNA-targeting CRISPR-Cas13d system, the investigators demonstrate highly selective cytotoxicity against tumor cells while largely preserving non-malignant tissues, an outcome that addresses one of the central challenges in precision oncology.

A Cancer with Unchanged Outcomes: Uveal Melanoma

Uveal melanoma represents the most common primary intraocular cancer in adults and remains the second-most prevalent form of melanoma overall. Originating from melanocytes located in the iris, ciliary body, or choroid, this disease is clinically notorious for its aggressive metastatic behavior. Approximately half of patients ultimately develop metastases, most frequently in the liver, where median survival typically ranges between 6 and 12 months. Despite advances in oncology, long-term survival statistics for uveal melanoma have remained largely unchanged for over 50 years.

Standard-of-care interventions are dominated by localized treatments such as plaque brachytherapy or proton beam radiation, often culminating in enucleation for disease control. While these modalities can limit primary tumor progression, they impose profound consequences for vision and quality of life. Therapeutic options for metastatic disease are exceptionally limited. Tebentafusp, the only FDA-approved agent specifically indicated for metastatic uveal melanoma, provides a modest survival extension and is restricted to patients with a specific HLA genotype, leaving the majority of patients without effective systemic therapies. Collectively, these realities underscore a persistent and substantial unmet medical need.

Targeting the “Undruggable” in Uveal Melanoma

To identify novel vulnerabilities, the Stanford team led by Lei S. Qi applied a data-driven discovery framework integrating large-scale functional genomics resources, including the Broad Institute’s DepMap dataset. Through systematic computational filtering of CRISPR dependency screens across more than 1,000 cancer cell lines, RasGRP3 (Ras Guanyl Releasing Protein 3) emerged as a compelling context-specific essential gene.

RasGRP3 displayed a striking dependency profile: uveal melanoma cells were highly reliant on its expression, whereas non-malignant cells were comparatively insensitive. Transcriptomic analyses further reinforced its relevance, revealing markedly elevated RasGRP3 expression in uveal melanoma relative to other cancers and healthy tissues, including normal ocular cells. Mechanistically, RasGRP3 functions downstream of oncogenic GNAQ and GNA11 mutations—canonical drivers of uveal melanoma—and serves as a key intermediary activating the RAS/RAF/MEK/ERK signaling axis.

Despite its biological significance, RasGRP3 has historically resisted conventional drug development strategies. Its intracellular localization precludes antibody-based targeting, and its structural features lack clear small-molecule binding pockets or enzymatic active sites. These characteristics place RasGRP3 within the class of “undruggable” targets that remain inaccessible to traditional therapeutic modalities.

A Dual-Mechanism CRISPR Strategy

To circumvent these limitations, the investigators employed CRISPR-Cas13d, an RNA-guided nuclease that selectively degrades messenger RNA rather than modifying genomic DNA. This distinction enables transient and programmable gene silencing without permanent genetic alterations—an attractive property for therapeutic applications.

A panel of 42 guide RNAs targeting RasGRP3 transcripts was screened for efficacy. The most potent candidate, termed g4, reduced tumor cell viability to near-complete levels while exerting minimal effects on non-cancerous cells. Importantly, mechanistic dissection revealed that Cas13d-mediated cytotoxicity was not solely attributable to RasGRP3 knockdown. Activated Cas13d also induced collateral RNA cleavage, a phenomenon in which additional cellular RNAs are degraded following target recognition.

Rather than representing a liability, this collateral activity enhanced therapeutic potency. The effect was preferentially observed in uveal melanoma cells exhibiting high RasGRP3 expression, thereby amplifying tumor-selective cytotoxicity. Rescue experiments using guide-resistant RasGRP3 constructs confirmed that the combined action of direct transcript degradation and collateral RNA cleavage produced synergistic cell killing, substantially exceeding the effects achieved by conventional gene-editing or RNA interference approaches.

Lipid Nanoparticle Delivery and Therapeutic Performance

Recognizing the importance of clinically viable delivery systems, the researchers encapsulated Cas13d mRNA and guide RNAs within lipid nanoparticles (LNPs), a platform with established translational success. After evaluating multiple formulations, an optimized LNP composition achieved high transfection efficiency in uveal melanoma models.

Across several independent tumor cell lines, the Cas13d-LNP therapeutic eliminated the vast majority of malignant cells within 48 hours, while non-malignant ocular cell models retained high viability. Comparative analyses indicated superior efficacy relative to Cas9-mediated DNA disruption and siRNA-based silencing, consistent with the added contribution of collateral RNA degradation.

Implications for Precision Oncology

Beyond uveal melanoma, the study illustrates a scalable target-to-therapy paradigm. By integrating computational dependency mapping, programmable RNA-targeting nucleases, and nanoparticle-based delivery, the framework offers a route for converting previously inaccessible intracellular proteins into actionable therapeutic targets. Computational analyses conducted by the authors further suggest that numerous additional context-specific essential genes across diverse malignancies may be amenable to similar strategies.

This approach represents a conceptual shift in drug discovery. Rather than relying on structural druggability constraints, RNA-targeting CRISPR systems enable direct functional suppression of disease-driving transcripts, potentially expanding the therapeutic landscape for cancers defined by challenging molecular targets.

Path Forward

While the reported findings are highly encouraging, further validation is required prior to clinical translation. Critical next steps include evaluation in patient-derived models, assessment of biodistribution and safety in vivo, and investigation of potential immune responses. The possibility of resistance remains an inherent consideration; however, the dual-mechanism nature of Cas13d activity may offer advantages in mitigating escape pathways. Strategies such as multiplexed guide RNAs or rational combination therapies may further enhance durability.

For uveal melanoma specifically, both localized ocular delivery and systemic administration targeting hepatic metastases present plausible clinical trajectories, particularly given the compatibility of LNP platforms with existing therapeutic pipelines.

Reference

Stauber D, Sosnick L, Ma Y, Pimcharoen S, Lawanprasert A, Murthy N, Myung D, Qi LS. CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma. Molecular Therapy: Oncology (2026). DOI: 10.1016/j.omton.2026.201151

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI).

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)